TECLens, a Stamford, CT-based clinical-stage ophthalmic medical device company, raised $9.3M in Series A funding.
The round was led by Johnson & Johnson Innovation – JJDC Inc. and Yonjin Capital, with participation from Rimonci Capital, and Sunmed Capital.
The company intends to use the funds for the clinical development of its non-incisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea.
Led by CEO Thomas Dunlap, TECLens is a clinical-stage ophthalmic medical device company, providing non-invasive, personalized corneal cross-linking technology (qCXL™) for vision correction. Its CXLens® system uses patterned ultraviolet (UV) light to gently reshape the cornea with continuous biomechanical control. qCXL™ is designed to be a comfortable, safe, and effective alternative to traditional refractive surgeries.
FinSMEs
11/02/2025